Issue 22: Pharmaceutical regulatory roundup

BY DR TIM SANDLE  | 27 June 2024

Catch up with the latest news from around the pharmaceutical industry with issue 22 of our regulatory review, curated by Dr Tim Sandle.

Pathogen safety

EMA has recently updated its position statement on Creutzfeldt-Jakob disease (CJD) and Plasma-Derived Medicinal Products (PDMPs), no longer classifying UK residence as a risk factor for transmission of variant CJD (vCJD) by PDMPs. In the revised statement, plasma from the UK, or from donors who have spent time in the UK (between 1980-1996) is "no longer considered to pose a health risk for recipients of plasma-derived medicinal products" based on the emerging clinical and epidemiological scientific evidence.